PARP1 and pancreatic ductal adenocarcinoma: [18F]olaparib was demonstrated to have good selectivity towards PARP1, 2 and 3 in pancreatic ductal adenocarcinoma (PDAC) preclinical models [6], making [18F]olaparib a good candidate as an imaging tool to study the effects of PARP inhibitor on PARP isoform expression.